Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer
Open Access
- 1 January 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (1), 6-9
- https://doi.org/10.1158/0008-5472.can-05-3389
Abstract
Uncontrolled cell division is an indispensable event in tumor progression, and numerous molecules involved in this process have been the focus of intense investigation in tumor biology. Cyclins, molecules that orchestrate normal cell cycle progression, are abnormally overexpressed in various human cancers. We review evidence that the immune system recognizes some abnormally expressed cyclins as tumor antigens, such as cyclin B1, and we analyze the potential of cyclins D, E, and A to serve a similar function in cancer immunosurveillance. (Cancer Res 2006; 66(1): 6-9)This publication has 15 references indexed in Scilit:
- Evaluation of Anticyclin B1 Serum Antibody as a Diagnostic and Prognostic Biomarker for Lung CancerAnnals of the New York Academy of Sciences, 2005
- Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcomeEuropean Journal of Haematology, 2005
- Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A ReviewClinical Cancer Research, 2005
- Cyclin E in normal and neoplastic cell cyclesOncogene, 2005
- Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor‐associated antigensThe Prostate, 2005
- T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant DiseaseClinical Cancer Research, 2005
- Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cellsOncogene, 2004
- MUC1 Immunobiology: From Discovery to Clinical ApplicationsAdvances in Immunology, 2004
- E- and A-type cyclins as markers for cancer diagnosis and prognosisExpert Review of Molecular Diagnostics, 2003
- Immune response to cyclin B1 in hepatocellular carcinomaHepatology, 1997